Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.

Apomine, a novel 1,1 bisphosphonate ester, increases the rate of degradation of HMG-CoA reductase, inhibiting the mevalonate pathway and thereby blocking cholesterol biosynthesis. We have investigated whether Apomine can induce myeloma cell apoptosis in vitro and modulate myeloma disease in vivo. Ap...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Edwards, C, Mueller, G, Roelofs, A, Chantry, A, Perry, M, Russell, R, Van Camp, B, Guyon-Gellin, Y, Niesor, E, Bentzen, C, Vanderkerken, K, Croucher, P
Format:	Journal article
Język:	English
Wydane:	2007

Podobne zapisy

Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro
od: Roelofs, A, i wsp.
Wydane: (2005)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
od: Croucher, P, i wsp.
Wydane: (2002)

Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
od: Roelofs, A, i wsp.
Wydane: (2007)

Novel insights into the anti-tumour mechanism of action of apomine and its synergistic interaction with lovastatin in myeloma cells in vitro
od: Roelofs, A, i wsp.
Wydane: (2006)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
od: Croucher, P, i wsp.
Wydane: (2003)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
od: Mueller, G, i wsp.
Wydane: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
od: Mueller, G, i wsp.
Wydane: (2004)

HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
od: Aronson, J, i wsp.
Wydane: (1990)

Pleiotropic effects of the HMG-CoA reductase inhibitors
od: Mihos CG, i wsp.
Wydane: (2011-04-01)

Regulation of HMG-CoA reductase activity in plants.
od: B A Stermer, i wsp.
Wydane: (1994-07-01)

Activation of HMG-CoA reductase by microsomal phosphatase
od: K R Feingold, i wsp.
Wydane: (1983-03-01)

The discovery and development of HMG-CoA reductase inhibitors.
od: A Endo
Wydane: (1992-11-01)

HMG-CoA reductase kinase: measurement of activity by methods that preclude interference by inhibitors of HMG-CoA reductase activity or by mevalonate kinase.
od: H J Harwood, Jr, i wsp.
Wydane: (1982-07-01)

Bisphosphonates--mechanisms of action in multiple myeloma.
od: Shipman, C, i wsp.
Wydane: (2000)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
od: Shipman, C, i wsp.
Wydane: (2000)

Osteoprotegerin and the development of myeloma bone disease
od: Croucher, P, i wsp.
Wydane: (2004)

HMG CoA reductase of intestinal mucosa and liver of the rat
od: S. Shefer, i wsp.
Wydane: (1972-05-01)

HMG-CoA reductase is not the site of the primary defect in phytosterolemia
od: G.M.B. Berger, i wsp.
Wydane: (1998-05-01)

Genetic and dietary interactions in the regulation of HMG-CoA reductase gene expression.
od: JJ Hwa, i wsp.
Wydane: (1992-05-01)

Bisphosphonates and in vivo models of multiple myeloma - Reply
od: Shipman, C, i wsp.
Wydane: (2001)

The prenyltransferase UBIAD1 is the target of geranylgeraniol in degradation of HMG CoA reductase
od: Marc M Schumacher, i wsp.
Wydane: (2015-03-01)

Stimulatory effect of dietary lipid and cholestyramine on hepatic HMG CoA reductase
od: Stanley Goldfarb, i wsp.
Wydane: (1972-11-01)

QSAR Regression Models for Predicting HMG-CoA Reductase Inhibition
od: Robert Ancuceanu, i wsp.
Wydane: (2024-10-01)

HMG-CoA Reductase Inhibitors from Monascus-Fermented Rice
od: Xuemei Li, i wsp.
Wydane: (2013-01-01)

Eupatilin Alleviates Hyperlipidemia in Mice by Inhibiting HMG-CoA Reductase
od: Kyung-Joo Kim, i wsp.
Wydane: (2023-01-01)

The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
od: Paolo Gelosa, i wsp.
Wydane: (2007-11-01)

Induction of HMG CoA reductase by the administration of 20,25-diazacholesterol
od: R Langdon, i wsp.
Wydane: (1977-01-01)

MTD–CoMSIA modelling of HMG-CoA reductase inhibitors
od: DANIEL M. DUDA-SEIMAN, i wsp.
Wydane: (2011-01-01)

Measurement of human leukocyte microsomal HMG-CoA reductase activity.
od: H J Harwood, Jr, i wsp.
Wydane: (1984-09-01)

Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo
od: Jobin Jean, i wsp.
Wydane: (2004-05-01)

Diurnal variation of HMG CoA reductase activity in rat intestine
od: S. Shefer, i wsp.
Wydane: (1972-09-01)

Chronic Onset Form of Anti-HMG-CoA Reductase Myopathy
od: Noel Lorenzo Villalba, i wsp.
Wydane: (2021-06-01)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
od: Croucher, P, i wsp.
Wydane: (2001)

Mutations within the membrane domain of HMG-CoA reductase confer resistance to sterol-accelerated degradation
od: Peter C.W. Lee, i wsp.
Wydane: (2007-02-01)

Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity
od: Gene C. Ness, i wsp.
Wydane: (1998-01-01)

Rapid reverse phase-HPLC assay of HMG-CoA reductase activity
od: Matteo Mozzicafreddo, i wsp.
Wydane: (2010-08-01)

Inactivation of rat liver HMG-CoA reductase phosphatases by polycarboxylic acids.
od: F G Hegardt, i wsp.
Wydane: (1983-07-01)

Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor
od: Sucharita Bose, i wsp.
Wydane: (2023-04-01)

Regulated degradation of HMG CoA reductase requires conformational changes in sterol-sensing domain
od: Hongwen Chen, i wsp.
Wydane: (2022-07-01)

Are Point Mutations in HMG-CoA Reductases (Hmg1 and Hmg2) a Step towards Azole Resistance in <i>Aspergillus fumigatus</i>?
od: Irene Gonzalez-Jimenez, i wsp.
Wydane: (2021-10-01)